Philippe Corcia

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3173823/publications.pdf

Version: 2024-02-01

142 papers	5,820 citations	81900 39 h-index	91884 69 g-index
161 all docs	161 docs citations	161 times ranked	8060 citing authors

#	Article	IF	Citations
1	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	8.1	517
2	Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurology, The, 2018, 17, 423-433.	10.2	342
3	SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. Journal of Medical Genetics, 2010, 47, 554-560.	3.2	266
4	Molecular Imaging of Microglial Activation in Amyotrophic Lateral Sclerosis. PLoS ONE, 2012, 7, e52941.	2.5	203
5	Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9004-9009.	7.1	177
6	Phenotype difference between ALS patients with expanded repeats inC9ORF72and patients with mutations in other ALS-related genes. Journal of Medical Genetics, 2012, 49, 258-263.	3.2	157
7	The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development. Current Medicinal Chemistry, 2014, 21, 3551-3575.	2.4	132
8	The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight?. Brain, 2019, 142, 1176-1194.	7.6	128
9	Progression in ALS is not linear but is curvilinear. Journal of Neurology, 2010, 257, 1713-1717.	3.6	124
10	Primary lateral sclerosis: consensus diagnostic criteria. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 373-377.	1.9	118
11	Initial evaluation in healthy humans of [18F]DPA-714, a potential PET biomarker for neuroinflammation. Nuclear Medicine and Biology, 2012, 39, 570-578.	0.6	115
12	Abnormal SMN1 gene copy number is a susceptibility factor for amyotrophic lateral sclerosis. Annals of Neurology, 2002, 51, 243-246.	5.3	111
13	Lipidomics Reveals Cerebrospinal-Fluid Signatures of ALS. Scientific Reports, 2017, 7, 17652.	3.3	110
14	Panel of Oxidative Stress and Inflammatory Biomarkers in ALS: A Pilot Study. Canadian Journal of Neurological Sciences, 2017, 44, 90-95.	0.5	105
15	Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology, 2019, 92, e1610-e1623.	1.1	105
16	A ferroptosisâ€“based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis. Scientific Reports, 2019, 9, 2918.	3.3	91
17	Epidemiology of amyotrophic lateral sclerosis: A review of literature. Revue Neurologique, 2016, 172, 37-45.	1.5	90
18	SMN1 gene, but not SMN2 , is a risk factor for sporadic ALS. Neurology, 2006, 67, 1147-1150.	1.1	80

#	Article	IF	Citations
19	Metabolomics in Cerebrospinal Fluid of Patients with Amyotrophic Lateral Sclerosis: An Untargeted Approach via High-Resolution Mass Spectrometry. Journal of Proteome Research, 2013, 12, 3746-3754.	3.7	77
20	Comparative analysis of targeted metabolomics: Dominance-based rough set approach versus orthogonal partial least square-discriminant analysis. Journal of Biomedical Informatics, 2015, 53, 291-299.	4.3	73
21	Phenotype and genotype analysis in amyotrophic lateral sclerosis with TARDBP gene mutations. Neurology, 2012, 78, 1519-1526.	1.1	72
22	Elevated Serum Ferritin Is Associated with Reduced Survival in Amyotrophic Lateral Sclerosis. PLoS ONE, 2012, 7, e45034.	2.5	72
23	Cubital tunnel syndrome: Comparative results of a multicenter study of 4 surgical techniques with a mean follow-up of 92months. Orthopaedics and Traumatology: Surgery and Research, 2014, 100, S205-S208.	2.0	70
24	Screening of OPTN in French familial amyotrophic lateral sclerosis. Neurobiology of Aging, 2011, 32, 557.e11-557.e13.	3.1	68
25	Age-dependent neurodegeneration and organelle transport deficiencies in mutant TDP43 patient-derived neurons are independent of TDP43 aggregation. Neurobiology of Disease, 2018, 115, 167-181.	4.4	67
26	A pharmaco-metabolomics approach in a clinical trial of ALS: Identification of predictive markers of progression. PLoS ONE, 2018, 13, e0198116.	2.5	64
27	Wildtype motoneurons, ALSâ€Linked SOD1 mutation and glutamate profoundly modify astrocyte metabolism and lactate shuttling. Glia, 2017, 65, 592-605.	4.9	62
28	Causative Genes in Amyotrophic Lateral Sclerosis and Protein Degradation Pathways: a Link to Neurodegeneration. Molecular Neurobiology, 2018, 55, 6480-6499.	4.0	59
29	Amyotrophic lateral sclerosis: A hormonal condition?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 585-588.	2.1	57
30	ALS and frontotemporal dementia belong to a common disease spectrum. Revue Neurologique, 2017, 173, 273-279.	1.5	56
31	Inhibition of Î²-Glucocerebrosidase Activity Preserves Motor Unit Integrity in a Mouse Model of Amyotrophic Lateral Sclerosis. Scientific Reports, 2017, 7, 5235.	3.3	53
32	Mutations of the ANG Gene in French Patients With Sporadic Amyotrophic Lateral Sclerosis. Archives of Neurology, 2008, 65, 1333.	4.5	52
33	Iron Metabolism Disturbance in a French Cohort of ALS Patients. BioMed Research International, 2014, 2014, 1-6.	1.9	52
34	Genetics of amyotrophic lateral sclerosis. Revue Neurologique, 2017, 173, 254-262.	1.5	52
35	How Can a Ketogenic Diet Improve Motor Function?. Frontiers in Molecular Neuroscience, 2018, 11, 15.	2.9	49
36	Phenotypes and malignancy risk of different FUS mutations in genetic amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2019, 6, 2384-2394.	3.7	49

#	Article	IF	Citations
37	Combined Metabolomics and Transcriptomics Approaches to Assess the IL-6 Blockade as a Therapeutic of ALS: Deleterious Alteration of Lipid Metabolism. Neurotherapeutics, 2016, 13, 905-917.	4.4	46
38	Untargeted ¹ H-NMR metabolomics in CSF. Neurology, 2014, 82, 1167-1174.	1.1	42
39	NSC-34 Motor Neuron-Like Cells Are Unsuitable as Experimental Model for Glutamate-Mediated Excitotoxicity. Frontiers in Cellular Neuroscience, 2016, 10, 118.	3.7	41
40	July 2017 ENCALS statement on edaravone. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 471-474.	1.7	41
41	Blood Cell Palmitoleate-Palmitate Ratio Is an Independent Prognostic Factor for Amyotrophic Lateral Sclerosis. PLoS ONE, 2015, 10, e0131512.	2.5	40
42	Omics to Explore Amyotrophic Lateral Sclerosis Evolution: the Central Role of Arginine and Proline Metabolism. Molecular Neurobiology, 2017, 54, 5361-5374.	4.0	40
43	Management of Amyotrophic Lateral Sclerosis. Drugs, 2008, 68, 1037-1048.	10.9	37
44	Disruption of TCA Cycle and Glutamate Metabolism Identified by Metabolomics in an In Vitro Model of Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2016, 53, 6910-6924.	4.0	37
45	Metabolomics in amyotrophic lateral sclerosis: how far can it take us?. European Journal of Neurology, 2016, 23, 447-454.	3.3	36
46	Genome-wide significant association ofANKRD55rs6859219 and multiple sclerosis risk. Journal of Medical Genetics, 2013, 50, 140-143.	3.2	34
47	Adjunctive perampanel in refractory epilepsy: Experience at tertiary epilepsy care center in Tours. Epilepsy and Behavior, 2016, 61, 237-241.	1.7	33
48	ATXN1 repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalization. Brain Communications, 2020, 2, fcaa064.	3.3	33
49	Improvement of a CIDP associated with hepatitis C virus infection using antiviral therapy. Neurology, 2004, 63, 179-180.	1.1	32
50	Vitamin D is Not a Protective Factor in <scp>ALS</scp>. CNS Neuroscience and Therapeutics, 2015, 21, 651-656.	3.9	32
51	Nutritional assessment of amyotrophic lateral sclerosis in routine practice: Value of weighing and bioelectrical impedance analysis. Muscle and Nerve, 2015, 51, 479-484.	2.2	32
52	Closing the case ofAPOEin multiple sclerosis: no association with disease risk in over 29â€...000 subjects: Figure 1. Journal of Medical Genetics, 2012, 49, 558-562.	3.2	31
53	Biomarkers in amyotrophic lateral sclerosis: combining metabolomic and clinical parameters to define disease progression. European Journal of Neurology, 2016, 23, 346-353.	3.3	31
54	The importance of theSMNgenes in the genetics of sporadic ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 436-440.	2.1	30

#	Article	IF	Citations
55	A Rare Motor Neuron Deleterious Missense Mutation in theDPYSL3(CRMP4) Gene is Associated with ALS. Human Mutation, 2013, 34, 953-960.	2.5	30
56	Biological followâ€up in amyotrophic lateral sclerosis: decrease in creatinine levels and increase in ferritin levels predict poor prognosis. European Journal of Neurology, 2015, 22, 1385-1390.	3.3	30
57	Protein SUMOylation, an emerging pathway in amyotrophic lateral sclerosis. International Journal of Neuroscience, 2013, 123, 366-374.	1.6	29
58	Management and therapeutic perspectives in amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics, 2017, 17, 263-276.	2.8	29
59	Isolated paralysis of the serratus anterior muscle: Surgical release of the distal segment of the long thoracic nerve in 52 patients. Orthopaedics and Traumatology: Surgery and Research, 2014, 100, S243-S248.	2.0	28
60	Is there a paraneoplastic ALS?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 252-257.	1.7	28
61	Liver X Receptor Genes Variants Modulate ALS Phenotype. Molecular Neurobiology, 2018, 55, 1959-1965.	4.0	28
62	Low IDL-B and high LDL-1 subfraction levels in serum of ALS patients. Journal of the Neurological Sciences, 2017, 380, 124-127.	0.6	27
63	The combination of four analytical methods to explore skeletal muscle metabolomics: Better coverage of metabolic pathways or a marketing argument?. Journal of Pharmaceutical and Biomedical Analysis, 2018, 148, 273-279.	2.8	27
64	Current view and perspectives in amyotrophic lateral sclerosis. Neural Regeneration Research, 2017, 12, 181.	3.0	26
65	Split-hand and split-limb phenomena in amyotrophic lateral sclerosis: pathophysiology, electrophysiology and clinical manifestations. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1126-1130.	1.9	25
66	N19S, a new SOD1 mutation in sporadic amyotrophic lateral sclerosis: No evidence for disease causation. Annals of Neurology, 2003, 53, 815-818.	5.3	23
67	Reconsidering the causality of TIA1 mutations in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 1-3.	1.7	22
68	Therapeutic news in ALS. Revue Neurologique, 2021, 177, 544-549.	1.5	22
69	Homozygous SMN2 deletion is a protective factor in the Swedish ALS population. European Journal of Human Genetics, 2012, 20, 588-591.	2.8	21
70	Neuroinflammation and ï¿½ Amyloid Deposition in Alzheimer's Disease: In vivo Quantification with Molecular Imaging. Dementia and Geriatric Cognitive Disorders, 2014, 37, 1-18.	1.5	21
71	A novel mutation of the C-terminal amino acid of FUS (Y526C) strengthens FUS gene as the most frequent genetic factor in aggressive juvenile ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 298-301.	1.7	21
72	Value of Nerve Biopsy in Patients With Latent Malignant Hemopathy and Peripheral Neuropathy. Medicine (United States), 2015, 94, e394.	1.0	20

#	Article	IF	Citations
73	New therapy options for amyotrophic lateral sclerosis. Expert Opinion on Pharmacotherapy, 2013, 14, 1907-1917.	1.8	19
74	Advances in Cellular Models to Explore the Pathophysiology of Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2014, 49, 966-983.	4.0	19
75	Primary lateral sclerosis may occur within familial amyotrophic lateral sclerosis pedigrees. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 154-156.	2.1	18
76	Peripheral Myelin Protein 22 gene duplication with atypical presentations: A new example of the wide spectrum of Charcot-Marie-Tooth 1A disease. Neuromuscular Disorders, 2014, 24, 524-528.	0.6	18
77	APOE Îµ4 allele is associated with an increased risk of bulbar-onset amyotrophic lateral sclerosis in men. European Journal of Neurology, 2011, 18, 1046-1052.	3.3	17
78	A novel SOD1 mutation p.V31A identified with a slowly progressive form of amyotrophic lateral sclerosis. Neurobiology of Aging, 2014, 35, 266.e1-266.e4.	3.1	17
79	Further development of biomarkers in amyotrophic lateral sclerosis. Expert Review of Molecular Diagnostics, 2016, 16, 853-868.	3.1	17
80	Exploring the diagnosis delay and ALS functional impairment at diagnosis as relevant criteria for clinical trial enrolment*. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 519-527.	1.7	17
81	Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole. Therapeutics and Clinical Risk Management, 2012, 8, 359.	2.0	16
82	Nerve Biopsy Is Still Useful in Some Inherited Neuropathies. Journal of Neuropathology and Experimental Neurology, 2018, 77, 88-99.	1.7	16
83	Frontotemporal Pathology in Motor Neuron Disease Phenotypes: Insights From Neuroimaging. Frontiers in Neurology, 2021, 12, 723450.	2.4	16
84	Pure cerebellar ataxia linked to large C9orf72 repeat expansion. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 301-303.	1.7	15
85	Sex-dependent effects of chromogranin B P413L allelic variant as disease modifier in amyotrophic lateral sclerosis. Human Molecular Genetics, 2016, 25, ddw304.	2.9	15
86	Are the clinical classifications for psychogenic nonepileptic seizures reliable?. Epilepsy and Behavior, 2017, 77, 53-57.	1.7	15
87	SMN1 gene study in three families in which ALS and spinal muscular atrophy co-exist. Neurology, 2002, 59, 1464-1466.	1.1	14
88	Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection. Expert Opinion on Pharmacotherapy, 2016, 17, 1669-1682.	1.8	14
89	Advances in disease-modifying pharmacotherapies for the treatment of amyotrophic lateral sclerosis. Expert Opinion on Pharmacotherapy, 2020, 21, 1103-1110.	1.8	14
90	Inhibition of Pathogenic Mutant SOD1 Aggregation in Cultured Motor Neuronal Cells by Prevention of Its SUMOylation on Lysine 75. Neurodegenerative Diseases, 2016, 16, 161-171.	1.4	13

#	Article	IF	Citations
91	Genetics of primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 28-34.	1.7	13
92	Breast cancer and motor neuron disease: Clinical study of seven cases. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 288-291.	2.1	12
93	The Metabolic Disturbances of Motoneurons Exposed to Glutamate. Molecular Neurobiology, 2018, 55, 7669-7676.	4.0	12
94	Staging amyotrophic lateral sclerosis: A new focus on progression. Revue Neurologique, 2019, 175, 277-282.	1.5	12
95	Somatosensory Evoked Potentials in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Journal of Clinical Neurophysiology, 2014, 31, 241-245.	1.7	11
96	A decrease in blood cholesterol after gastrostomy could impact survival in ALS. European Journal of Clinical Nutrition, 2017, 71, 1133-1135.	2.9	11
97	Mutation in the RRM2 domain of TDP-43 in Amyotrophic Lateral Sclerosis with rapid progression associated with ubiquitin positive aggregates in cultured motor neurons. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 149-151.	1.7	11
98	The Wide Spectrum of Pathophysiologic Mechanisms of Paraproteinemic Neuropathy. Neurology, 2021, 96, 214-225.	1.1	11
99	The hypometabolic state: a good predictor of a better prognosis in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 41-47.	1.9	11
100	Functional Outcome of Hemorrhagic Transformation after Thrombolysis for Ischemic Stroke: A Prospective Study. Cerebrovascular Diseases Extra, 2015, 5, 103-106.	1.5	10
101	Therapeutic options and management of polyneuropathy associated with anti-MAG antibodies. Expert Review of Neurotherapeutics, 2016, 16, 1111-1119.	2.8	10
102	The Effect of <scp>SMN</scp> Gene Dosage on <scp>ALS</scp> Risk and Disease Severity. Annals of Neurology, 2021, 89, 686-697.	5.3	10
103	Dysregulations of Expression of Genes of the Ubiquitin/SUMO Pathways in an In Vitro Model of Amyotrophic Lateral Sclerosis Combining Oxidative Stress and SOD1 Gene Mutation. International Journal of Molecular Sciences, 2021, 22, 1796.	4.1	10
104	Association study of the ubiquitin conjugating enzyme gene UBE2H in sporadic ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 432-435.	2.1	9
105	Familial clustering of primary lateral sclerosis and amyotrophic lateral sclerosis: Supplementary evidence for a continuum. European Journal of Neurology, 2021, 28, 2780-2783.	3.3	9
106	Benign lower limb amyotrophy due to TARDBP mutation or post-polio syndrome?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 476-478.	1.7	8
107	Phenotypic and genotypic studies of ALS cases in ALS-SMA families. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 432-437.	1.7	8
108	Is There a Role for Vitamin D in Amyotrophic Lateral Sclerosis? A Systematic Review and Meta-Analysis. Frontiers in Neurology, 2020, 11, 697.	2.4	8

#	Article	IF	Citations
109	Pre-symptomatic diagnosis in ALS. Revue Neurologique, 2020, 176, 166-169.	1.5	8
110	Typical bulbar ALS can be linked to GARS mutation. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 275-277.	1.7	7
111	Effect of familial clustering in the genetic screening of 235 French ALS families. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 479-484.	1.9	7
112	Impact of a frequent nearsplice SOD1 variant in amyotrophic lateral sclerosis: optimising SOD1 genetic screening for gene therapy opportunities. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 942-949.	1.9	7
113	Metabolic Profile and Pathological Alterations in the Muscle of Patients with Early-Stage Amyotrophic Lateral Sclerosis. Biomedicines, 2022, 10, 1307.	3.2	7
114	CADASIL and ALS: A link?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 399-401.	2.1	6
115	Respiratory onset in an ALS family with L144F SOD1 mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 747-749.	1.9	6
116	A common functional allele of the Nogo receptor gene, reticulon 4 receptor (RTN4R), is associated with sporadic amyotrophic lateral sclerosis in a French population. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 490-496.	1.7	6
117	A novel p.E121G SOD1 mutation in slowly progressive form of amyotrophic lateral sclerosis induces cytoplasmic aggregates in cultured motor neurons and reduces cell viability. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 131-134.	1.7	6
118	Brait-Fahn-Schwarz disease: The missing link between ALS and Parkinson's disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 135-136.	1.7	5
119	In ALS, a mutation could be worth two steps. Revue Neurologique, 2018, 174, 669-670.	1.5	5
120	Co-occurrence of MS and ALS: a clue in favor of common pathophysiological findings?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 500-505.	1.7	5
121	Ferritin and LDL-cholesterol as biomarkers of fat-free mass loss in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 441-444.	1.7	4
122	Development of permanent brain damage after subacute encephalopathy with seizures in alcoholics. Journal of the Neurological Sciences, 2019, 396, 12-17.	0.6	4
123	Clinical trials in pediatric ALS: a TRICALS feasibility study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 481-488.	1.7	3
124	Inborn Errors of Metabolism in Elderly Adults. Journal of the American Geriatrics Society, 2016, 64, e57-8.	2.6	2
125	Pseudo spastic gait can reveal a Stiff Leg Syndrome (SLS). Clinical Neurology and Neurosurgery, 2016, 147, 108-109.	1.4	2
126	<scp>SOD</scp>1 mutation can mask C9<scp>orf</scp>72 abnormal expansion. European Journal of Neurology, 2017, 24, e24.	3.3	2

#	Article	IF	Citations
127	C-reactive protein: A promising biomarker in ALS?. Revue Neurologique, 2018, 174, 104-105.	1.5	2
128	Neurolysis of the distal segment of the long thoracic nerve for the treatment of scapular winging due to serratus anterior palsy: a continuous series of 73 cases. Journal of Shoulder and Elbow Surgery, 2022, 31, 2140-2146.	2.6	2
129	Absence of the OPTN mutation in a patient with ALS and familial primary open angle glaucoma. Journal of the Neurological Sciences, 2011, 309, 16-17.	0.6	1
130	Biological and neuroimaging biomarkers for amyotrophic lateral sclerosis: 2013 and beyond. Neurodegenerative Disease Management, 2013, 3, 427-444.	2.2	1
131	Development of monoclonal antibodies to human kallikrein-related peptidase 6 (KLK6) and their use in an immunofluorometric assay for free KLK6. Biological Chemistry, 2014, 395, 1119-1126.	2.5	1
132	Amyotrophic Lateral Sclerosis and Dementia. , 2015, , 23-34.		1
133	Simultaneous Combined Myositis, Inflammatory Polyneuropathy, and Overlap Myasthenic Syndrome. Case Reports in Neurological Medicine, 2016, 2016, 1-11.	0.4	1
134	An UPLC-MSMS method to measure plasma homocysteine concentration. Annales De Biologie Clinique, 2017, 75, 334-338.	0.1	1
135	A novel mutation in the cleavage site N291 of TDP-43 protein in a familial case of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 463-466.	1.7	1
136	The future of ALS might move towards Genetic Therapy. Revue Neurologique, 2021, 177, 613-614.	1.5	1
137	VEXAS syndrome extends the neurological complications of haemopathies. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 685-685.	1.9	1
138	Genetica della sclerosi laterale amiotrofica. EMC - Neurologia, 2008, 8, 1-8.	0.0	0
139	Distribution physiologique cÃ©rÃ©brale et corps entier du 18F-DPA-714Âen TEP/TDM. Medecine Nucleaire, 2013, 37, 44-51.	0.2	0
140	Quelle place pour lâ€™enquÃªte familiale dans la sclÃ©rose latÃ©rale amyotrophiqueÂ?. Pratique Neurologique - FMC, 2014, 5, 95-98.	0.1	0
141	Syndrome tunnel cubitalÂâ€“ÂÃ‰tude comparative multicentrique de 4Âtechniques chirurgicales avec 92mois de recul. Revue De Chirurgie Orthopedique Et Traumatologique, 2014, 100, S1-S5.	0.0	0
142	Reply to the letter from Gazulla. European Journal of Neurology, 2022, 29, e3-e4.	3.3	0